---
title: "Steris | 8-K: FY2027 Q1 Revenue Misses Estimate at USD 1.493 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295018577.md"
datetime: "2026-08-05T21:23:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295018577.md)
  - [en](https://longbridge.com/en/news/295018577.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295018577.md)
generator: "portal-rs"
---

# Steris | 8-K: FY2027 Q1 Revenue Misses Estimate at USD 1.493 B

Revenue: As of FY2027 Q1, the actual value is USD 1.493 B, missing the estimate of USD 1.495 B.

EPS: As of FY2027 Q1, the actual value is USD 2.04, beating the estimate of USD 1.982.

EBIT: As of FY2027 Q1, the actual value is USD 298.5 M.

STERIS plc announced a targeted consolidation plan involving the centralization of manufacturing and distribution for formulated chemistries into a new Center of Excellence in North Carolina, which includes the expected closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota. STERIS plc projects total pre-tax restructuring charges of approximately $55 million to $70 million, with completion expected during fiscal 2030. These charges are composed of $40 million to $50 million in cash expenditures and $15 million to $20 million in non-cash charges. These projected charges will be excluded from adjusted earnings measurements.

### Related Stocks

- [STE.US](https://longbridge.com/en/quote/STE.US.md)

## Related News & Research

- [STERIS Stock Outlook: Is Wall Street Bullish or Bearish?](https://longbridge.com/en/news/297032161.md)
- [STERIS (STE) Looks Modestly Undervalued, Is The Recent Pullback A Better Entry Point?](https://longbridge.com/en/news/293875350.md)
- [Steris PLC Stock Underperforms Monday When Compared To Competitors](https://longbridge.com/en/news/296146462.md)
- [Does STERIS' (STE) 21-Year Dividend Streak Reveal Its True Capital Allocation Priorities?](https://longbridge.com/en/news/294575259.md)
- [Steris Q1 adjusted EPS beats estimates, revenue up 7%](https://longbridge.com/en/news/295012873.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**